Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00657007 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)
A Phase 1 study, sponsored by Human Genome Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
NCT00657007 is a Phase 1 study that has completed, run by Human Genome Sciences. The registered enrollment target is 70 participants.
The verdict
NCT00657007, a Phase 1 study, has completed, sponsored by Human Genome Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
Study Summary
The purpose of thie study is to evaluate the safety, tolerability, immunogenicity, pharmacokinetics and pharmacodynamics of belimumab (LymphoStat-B™)in subjects with SLE.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL belimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2002-02 |
| Est. Completion | 2003-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00657007
The ClinicalTrials.gov registry entry for NCT00657007 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Human Genome Sciences, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00657007 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00657007 about?
NCT00657007 is a clinical study titled "Phase 1 Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)". The purpose of thie study is to evaluate the safety, tolerability, immunogenicity, pharmacokinetics and pharmacodynamics of belimumab (LymphoStat-B™)in subjects with SLE.
What is the current status of trial NCT00657007?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2002-02. Estimated completion is 2003-03.
What interventions are being tested in trial NCT00657007?
The interventions under investigation include: Placebo (BIOLOGICAL), belimumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00657007?
This trial is sponsored by Human Genome Sciences, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.